ABCL
AbCellera Biologics Inc. [ABCL] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
ABCL Stock Summary
Top ABCL Correlated Resources
ABCL
Top 10 Correlated ETFs
ABCL
Top 10 Correlated Stocks
ABCL
In the News
ABCL Financial details
Company Rating
-
Market Cap
1.27B
Income
-146.4M
Revenue
38.03M
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
586
Optionable
No
Shortable
Yes
Earnings
07 May 2024
P/E
-12.8
Forward P/E
-
PEG
-
P/S
32.88
P/B
1.4
P/C
-
P/FCF
-24.1
Quick Ratio
7.81
Current Ratio
8.34
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-0.51
EPS next Y
-
EPS next Q
-
EPS this Y
-
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
39.1%
EPS Q/Q
61.94%
-
-
-
-
SMA20
33.33%
SMA50
100%
SMA100
166.67%
Inst Own
-
Inst Trans
-
ROA
-9%
ROE
-11%
ROC
-0.15%
Gross Margin
97%
Oper. Margin
-405%
Profit Margin
-256%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
3.87-8.05
52W High
-16.06%
52W Low
+123.83%
RSI
54
Rel Volume
3.03
Avg Volume
1.43M
Volume
4.32M
Perf Week
-14.46%
Perf Month
23.44%
Perf Quarter
60.65%
Perf Half Y
80.51%
-
-
-
-
Beta
0.377
-
-
Volatility
0.44%, 0.99%
Prev Close
-7.89%
Price
6.715
Change
-4.21%
Company Profile
- Volume Average 1.43M
- Market Capitalization 1.27B
- Employee 586
- CEO Dr. Carl L.G. Hansen Ph.D.
- Headquarters Vancouver,BC,CA
- IPO Date 2020-12-11
-
Website
https://www.abcellera.com 
AbCellera Biologics Inc. develops antibody discovery platform. Its full-stack, artificial intelligence-powered antibody discovery platform searches and analyzes the database of natural immune systems to find antibodies that could be developed as drugs. As of December 31, 2021, the company had 156 discovery programs that are either completed, in progress, or under contract with 36 partners. AbCellera Biologics Inc. has a research collaboration and license agreement with Eli Lilly and Company. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.
